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Purpose: Accurate staging modalities to diagnose lymph node involvement in patients with prostate cancer (PCa) are lacking. We wanted
to prospectively assess sensitivity, speciﬁcity, and positive predictive value (PPV) and negative predictive value of 11C-choline positron
emission tomography (PET)-computed tomography (CT) and diffusion-weighted (DW) magnetic resonance imaging (MRI) for nodal staging
in patients with PCa at high risk for lymph node involvement.
Material and methods: In total, 75 patients with a riskZ10% buto35% for lymph node (LN) metastases (Partin tables) who had N0
lesions based on the ﬁndings of contrast-enhanced CT scans were included. Patients underwent 11C-choline PET-CT and DW MRI before
surgery, which consisted of a superextended lymph node dissection followed by radical prostatectomy. LNs were serially sectioned and
histopathologically examined after pankeratin staining. These results were used as the gold standard to compare with the imaging results.
Results: Of 1,665 resected LNs (median ¼ 21, range: 7–49), 106 affected LNs (median ¼ 2, range: 1–10) were found in 37 of 75
patients (49%). On a region-based analysis, we found a low sensitivity of 8.2% and 9.5% and a PPV of 50.0% and 40.0% for 11C-choline
PET-CT and DW MRI, respectively. The patient-based analysis showed a sensitivity of 18.9% and 36.1% for and a PPV of 63.6%
and 86.7% 11C-choline PET-CT and DW MRI, respectively. Even when both imaging modalities were combined, sensitivity values
remained too low to be clinically useful..urolonc.2014.11.008
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L. Van den Bergh et al. / Urologic Oncology: Seminars and Original Investigations ] (2015) 1–92Conclusions: Because of the low sensitivity, there is no indication for routine clinical use of either 11C-choline PET-CT or DW MRI for
LN staging in patients with PCa, in whom CT scan ﬁndings were normal. r 2015 Elsevier Inc. All rights reserved.
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Accurate staging modalities to diagnose lymph node
involvement (LNI) in patients with prostate cancer (PCa) are
currently lacking. Conventional imaging modalities used for
lymph node (LN) evaluation, i.e., contrast-enhanced computed
tomography (CT) and T2-weighted magnetic resonance imag-
ing (MRI), rely on size criteria next to other characteristics,
such as contrast enhancement, shape, localization, and lack of
central (hilar) fat to classify LN [1]. In a meta-analysis from
Hövels et al. [2], 24 studies published between 1980 and 2003
were included, demonstrating a pooled sensitivity of approx-
imately 40% for both CT and MRI. This low sensitivity for CT
scan was conﬁrmed in a large cohort of contemporary patients
by Briganti et al. [3], even in patients at high risk for LNI.
Given these signiﬁcant limitations, only an extended lymph
node dissection ensures a full nodal staging at present [4]. This
invasive procedure is, however, associated with a certain risk
of complications, and the search for alternative approaches is
therefore still warranted [5]. In recent years, promising new
functional imaging modalities such as choline positron emis-
sion tomography (PET)-CT scan and diffusion-weighted
(DW) MRI have been introduced. Carbon-11-labeled choline
(11C-choline) is a radiopharmaceutical that is potentially useful
for tumor imaging, as it is incorporated in cell membranes of
proliferating cells in the form of phosphatidylcholine. As PCa
is associated with increased cell proliferation and choline-
kinase upregulation, there is evidence that choline can be used
to visualize nodal metastases [6]. DW imaging measures the
amount of water diffusion in tissue that occurs by applying a
pair of strong gradient pulses and can provide information on
tissue cellularity and cell membrane integrity. Data on nodal
staging for PCa using DW MRI are rare, but encouraging
results have been reported in other cancer types [7,8].
The objective of this study was to prospectively assess the
performance of 11C-choline PET-CT and DW MRI for nodal
staging in patients at high risk for LNI, using histopathology
as the gold standard. We hereby report the ﬁnal results of a
previously published interim analysis on 36 patients [9].2. Material and methods
2.1. Patients
Between February 2008 and February 2011, 75 consec-
utive patients with localized, biopsy-proven prostate adeno-
carcinoma were scheduled for radical prostatectomy (RP) and
superextended lymph node dissection (seLND). The primary
tumor was staged by digital rectal examination andtransrectal ultrasound, a contrast-enhanced CT scan was
performed for nodal staging and patients were screened for
the presence of bone metastases with bone scintigraphy.
Patients younger than 75 years were prospectively selected
based on their risk for LNI, which had to beZ10%
buto35% according to the Partin tables. As no predictive
model existed for cT3 at the time of the study conception,
cT3 tumors were considered stage cT2c. Other selection
criteria were no evidence for pelvic LNI (i.e., no LN
Z 8 mm in transverse dimension on contrast-enhanced CT
scan) or bone metastasis, World Health Organization per-
formance statuso2, no previous therapy, and no previous/
other malignancy. All patients underwent preoperative 11C-
choline PET-CT and DW MRI. The study was approved by
the local ethics committee, and written informed consents
were obtained.
2.2. 11C-choline PET-CT
11C-choline PET-CT images were acquired using an
integrated Siemens Biograph Hirez 16-slice lutetium oxy-
orthosilicate PET-CT system (Siemens Medical, Erlangen,
Germany) after at least 6 hours of fasting. Immediately after
injection of 740 to 1,000 mBq 11C-choline, a contrast-
enhanced CT scan (3.3-mm slice thickness) was performed
with 120-ml nonionic contrast agent given intravenously as a
bolus (Ultravist, Schering) followed by the 11C-choline PET
emission scan. PET data of the whole-body tracer distribu-
tion were then acquired (6 bed positions, 5-min scanning
time per position) starting approximately 4 minutes after
injection. Images were iteratively reconstructed using
Ordered Subsets Expectation Maximization (5 iterations
and 8 subsets) with an in-plane Gaussian postreconstruction
smoothing of 6 mm. Attenuation correction was performed
using the CT data. All scans were analyzed by an experi-
enced member of the nuclear medicine department (C.M.D.)
who was blinded from all other data. Sites of pathological
11C-choline uptake were compared with background activity
and were assigned to an LN region based on the CT images.
2.3. Magnetic resonance imaging
Pelvic MRI was performed on a 1.5-T magnetic reso-
nance unit (SonataVision; Siemens, Erlangen, Germany)
using a combination of a 6-channel phased-array body coil
and spine coil. T2-weighted turbo spin-echo images were
obtained in the axial, coronal, and sagittal plane for
morphological evaluation (Supplementary Table). A DW
spin-echo echo-planar MRI was performed in the axial
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repetition time/echo time ¼ 4,000/79 ms, voxel size ¼
3.0  3.0 mm2. The acquisition time was 5 minutes and
3 seconds. Six b values (b ¼ 0, 50, 100, 500, 750, and
1,000 s/mm²) were used, and an apparent diffusion coef-
ﬁcient (ADC) map was automatically calculated by the
scanner's software. Image analysis was performed by an
experienced radiologist (R.O.) who marked the exact
location of the suspect nodes on a standardized template
while being blinded from all other data. The criterion for
probable presence of metastasis was a low ADC value.2.4. Surgery
Surgery was performed by an experienced urologist
(S.J.) and consisted of a bilateral seLND and open RP.
This seLND included all nodal/ﬁbrofatty tissue at the
common, external, and internal iliac regions, obturator
fossa, and presacral region. In most cases, all presacralTable 1
Patient and tumor characteristics
Total
(n ¼
Age (median þ range) 64.6
Preoperative PSA level, ng/ml (median þ range) 10.










7 (3 þ 4) 2
7 (4 þ 3) 1
8 2
9 (4 þ 5)
9 (5 þ 4)
10







7 (3 þ 4) 1
7 (4 þ 3) 2
8 1
9 (4 þ 5) 1
9 (5 þ 4)
10
Predicted risk for LNI according to the Partin tables (median þ range) 12%
Nodes examined per patient (median þ range) 2
PSA ¼ prostate-speciﬁc antigen.
Numbers between parentheses are percentages unless indicated otherwise.nodes were removed through a right-sided approach, as the
left common iliac vein prohibited a safe left-sided approach.
Therefore, this area was considered as a single region,
whereas other regions were dissected bilaterally. In addition
to these 9 “standard” regions, sentinel LN that were
detected outside the seLND template with a gamma probe
a few hours after intraprostatic radiocolloid injection were
resected only if technically justiﬁed (e.g., in the pararectal,
paravesical, or para-aortic region). All lymphatic tissue was
prospectively collected and mapped on a template repre-
senting the aforementioned anatomical regions.2.5. Histological examination
All the labeled specimens were delivered to the pathology
department on the standardized templates. LNs were ﬁxed
overnight in 6% formalin. All stations were examined by
palpation, visual inspection, and sectioning. The lamellated
(1-mm sections) LNs were then embedded in parafﬁn and75)
Patients with negative LN
(n ¼ 38)
Patients with positive LN
(n ¼ 37)
y (49.2–73.9) 65.2 y (51.8–73.2) 64.1 y (49.2–73.9)
4 (1.5–70.9) 10.1 (1.5–70.9) 10.6 (5.0–25.0)
1 (1.3) 0 (0.0) 1 (2.7)
2 (2.6) 1 (2.6) 1 (2.7)
3 (4.0) 2 (5.3) 1 (2.7)
4 (18.7) 11 (28.9) 3 (8.1)
3 (57.3) 23 (60.5) 20 (54.1)
1 (14.7) 1 (2.6) 10 (27.0)
1 (1.3) 0 (0.0) 1 (2.7)
2 (2.6) 2 (5.3) 0 (0.0)
3 (30.7) 16 (42.1) 7 (18.9)
7 (22.7) 6 (15.8) 11 (29.7)
1 (28.0) 9 (23.7) 12 (32.4)
9 (12.0) 3 (7.9) 6 (16.2)
2 (2.6) 2 (5.3) 0 (0.0)
1 (1.3) 0 (0.0) 1 (2.7)
2 (2.6) 2 (5.3) 0 (0.0)
1 (41.3) 24 (63.2) 7 (18.9)
0 (26.7) 10 (26.3) 10 (27.0)
9 (25.3) 0 (0.0) 19 (51.4)
3 (4.0) 2 (5.3) 1 (2.7)
8 (24.0) 15 (39.5) 3 (8.1)
5 (33.3) 16 (42.1) 9 (24.3)
4 (18.7) 2 (5.3) 12 (32.4)
5 (20.0) 4 (10.5) 11 (29.7)
2 (2.6) 1 (2.6) 1 (2.7)
1 (1.3) 0 (0.0) 1 (2.7)
(10–29%) 11.5% (10–29%) 12% (10–29%)
1 (7–49) 21 (7–42) 21 (10–49)
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immunohistochemically stained for pankeratin (monoclonal
Ab, clone AE1/AE3, Ready-to-Use, Dako, Denmark—auto-
matic staining [Dako PT Link, Dako, Denmark]). All slides
were microscopically evaluated for the presence of meta-
stases by an experienced uropathologist (E.L.). The maximal
diameter of each metastasis was noted and categorized in
macrometastases (Z2 mm), micrometastases (40.2 and
o2 mm) and isolated tumor cells (r0.2 mm) [10].
Prostatectomy specimens were handled according to the
guidelines [11]. Gleason scores were determined and
tumors were pathologically staged according to the 2002
TNM classiﬁcation.2.6. Statistics
Sensitivity, speciﬁcity, positive predictive value (PPV)
and negative predictive value, accuracy, and 95% CIs of the
imaging modalities were calculated on a patient- and
region-based basis. The region-based analysis was done
using a logistic generalized estimating equation model to
take the correlation between the different regions within one
patient into account.Fig. 1. Representative image of a patient with abnormal ﬁndings on 11C-choline P
The hot spot in the right external iliac region represents a positive LN, which was3. Results
Patient and tumor characteristics are depicted in Table 1.
The seLND yielded up to 1,665 LNs with a median of 21
(range: 7–49) nodes per patient. In total, 37 of 75 patients
(49%) were found to be node positive (Nþ) with 106 affected
LNs (median ¼ 2, range: 1–10). Affected LNs were located in
the internal iliac region (n ¼ 35), the external iliac region (n
¼ 30), the obturator fossa (n ¼ 26), the presacral (n ¼ 9),
common iliac (n ¼ 5), and aortic bifurcation region (n ¼ 1).
In total, 47 (44%) were macrometastases (median diameter ¼
4.0 mm, range: 2.1–10.0 mm), 47 (44%) were micrometastases
(median diameter ¼ 0.673 mm, range: 0.207–1.871 mm), and
12 (11%) were classiﬁed as isolated tumor cells (median
diameter ¼ 0.088 mm, range: 0.037–0.190 mm).
Images of a patient who had abnormal ﬁndings on an
11C-choline PET-CT and a patient who had positive ﬁndings
on DW MRI are shown in Figs. 1 and 2, respectively. The
median time between MRI or 11C-choline PET-CT and RP was
16 (interquartile range: 7–26) and 14 (interquartile range: 6–22)
days, respectively. Regions that were reported to be Nþ based
on the imaging results were only included if a histopathological
reference was available. In most patients, the 9 “standard”
regions could be analyzed. In 14 patients, 10 regions were
examined guided by a sentinel node detection, whereas inET. (A) 11C-choline PET, (B) contrast-enhanced CT, and (C) fusion image:
conﬁrmed on histopathology. (Color version of ﬁgure is available online.)
Fig. 2. Representative image of a patient with abnormal ﬁndings on DW MRI. (A) Diffusion-weighted MR image (b1000) showing a hyperintense LN in the
left internal iliac region (B), which correlates with a lymph node on T2-weigthed MRI considered to be affected.
Table 2
Number of true positives, true negatives, false positives, and false negatives
and sensitivity, speciﬁcity, and accuracy for nodal staging of 11C-choline
PET-CT (75 patients) and diffusion-weighted MRI (74 patients)
Patient-based analysis Region-based analysis
11C-choline PET-CT
True positive 7 Patients 7 LN regions
True negative 34 Patients 588 LN regions
False positive 4 Patients 7 LN regions
False negative 30 Patients 78 LN regions
Sensitivity 18.9% (6.1%–31.7%) 8.2% (1.7%–14.8%)
Speciﬁcity 89.5% (79.6%–99.4%) 98.8% (97.8%–99.9%)
PPV 63.6% (33.8%–93.5%) 50.0% (17.2%–82.8%)
NPVa 53.1% (40.8%–65.4%) 88.3% (84.6%–92.0%)
Accuracy 54.7% (43.3%–66.0%) 87.5% (83.9%–91.1%)
DW MRI
True positive 13 Patients 8 LN regions
True negative 36 Patients 575 LN regions
False positive 2 Patients 12 LN regions
False negative 23 Patients 76 LN regions
L. Van den Bergh et al. / Urologic Oncology: Seminars and Original Investigations ] (2015) 1–9 56 and 1 patient lymphatic tissue could only be obtained from 8
and 6 regions, respectively, owing to technical difﬁculties, e.g.,
preperitoneal mesh. For the DW MRI analysis, 1 patient was
excluded because of uninterpretable images owing to a hip
replacement. On a per-region analysis, we found a low
sensitivity of 8.2% and 9.5% for 11C-choline PET-CT and
DW MRI, respectively. Correspondingly, PPV was 50.0% and
40.0% for these imaging modalities. At patient-based analysis,
sensitivity increased to 18.9% and 36.1% for 11C-choline PET-
CT and DW MRI, with a PPV of 63.6% and 86.7%,
respectively. Detailed results are summarized in Table 2.
Table 3 provides an overview of the 37 node-positive
patients with details on the affected LNs and LN regions per
patient and the respective functional imaging results. 11C-
choline PET-CT correctly staged 7 patients and 7 LN
regions as Nþ and DW MRI 13 patients and 8 LN regions.
The average size on the pankeratin-stained section of LN
that were described as malignant based on 11C-choline PET-
CT and DW MRI ﬁndings was 3.554  3.922 mm and
5.070  3.026 mm, respectively.
Furthermore, the region-based analysis was repeated
excluding all affected LNs smaller than 2 mm, as such a
low tumor burden is under the detection threshold of the
imaging modalities. For 11C-choline PET-CT, sensitivity
levels decreased from 8.2% to 7.3%, whereas DW MRI
showed an increase in sensitivity from 9.5% to 17.5%.
Finally, the combination of both imaging modalities was
investigated (i.e., 11C-choline PET-CT or DW MRI pos-
itive), which resulted in an increased sensitivity to 16.7%
and 44.4% together with a PPV of 42.4% and 72.7% for the
region-based and patient-based analysis, respectively.
Details are shown in Table 4.Sensitivity 36.1% (20.2%–52.0%) 9.5% (3.6%–15.4%)
Speciﬁcity 94.7% (87.5%–100%) 98.0% (96.6%–99.3%)
PPV 86.7% (68.9%–100%) 40.0% (18.9%–61.1%)
NPV 61.0% (48.5%–73.6%) 88.3% (84.6%–92.1%)
Accuracy 66.2% (55.4%–77.1%) 86.9% (83.0%–90.8%)
NPV ¼ negative predictive value.
aNumbers between parentheses are 95% CIs.4. Discussion
According to the current guidelines, pelvic lymph node
dissection remains the most reliable staging method giventhe signiﬁcant limitations of preoperative imaging in the
detection of small metastases (o5 mm) [4].
With this study, we aimed at prospectively assessing the
role of 2 functional imaging modalities for N staging that
enable the visualization of functional features such as cell
proliferation (11C-choline PET-CT) and cellularity (DW
MRI). The current results conﬁrm those of our previously
published interim analysis on 36 patients, using routine
hematoxylin and eosin staining for histopathological eval-
uation of the LN [9]. Meanwhile, patient inclusion was
ﬁnalized at 75 patients and serial sections from 1,665 LNs
were evaluated after pankeratin staining to assure that all
Table 3





















Size of TP Nþ on
pankeratin-stained
sections, mmITC Micro Macro
2 1 1 0 0 1 (9) – – – – – –
6 4 0 3 1 3 (9) – – – – – –
7 1 0 1 0 1 (9) – – – Ext_R N –
8 9 1 5 3 4 (9) Ext_R,
Ext_L
Y, Y 3.650, 8.000 Int_R Y 4.500
9 1 0 0 1 1 (10) AoBif Y 10.000 AoBif Y 10.000
13 6 0 1 5 4 (9) – – – Int_R Y 6.000
14 2 0 1 1 2 (9) – – – Obt_R Y 7.000
17 1 0 0 1 1 (9) – – – – – –
18 3 1 1 1 3 (9) – – – – – –
19 2 0 2 0 2 (10) Ext_L Y 0.263 Int_L N –
20 2 0 1 1 2 (9) – – – Int_L Y 5.000
21 1 0 1 0 1 (9) Ext_R N – – – –
22 4 1 0 3 4 (9) – – – – – –
24 2 0 2 0 2 (9) – – – – – –
25 4 1 1 2 3 (9) Ext_L Y 1.476 Int_R Y 5.000
29 2 0 1 1 2 (8) – – – – – –
30 3 1 2 0 3 (9) Ext_L Y 0.600 – – –
35 1 0 1 0 1 (9) – – – Int_L N –
38 4 0 0 4 4 (9) – – – Obt_L Y 2.100
41 2 0 0 2 2 (9) – – – Obt_R N –
45 1 0 0 1 1 (9) – – – Ext_L and
Obt_L
N, N –
46 1 0 0 1 1 (9) – – – – – –
48 4 0 3 1 3 (8) – – – – – –
51 4 0 4 0 3 (9) – – – – – –
53 1 0 1 0 1 (9) – – – – – –
56 1 0 0 1 1 (9) – – – MRI uninterpretable owing to hip prosthesis
57 5 3 0 2 4 (10) – – – – – –
59 1 0 1 0 1 (9) Ext_L Y 0.889 – – –
61 1 1 0 0 1 (8) – – – – – –
62 2 0 0 2 1 (10) – – – – – –
63 8 0 3 5 5 (9) – – – – – –
66 10 0 4 6 7 (9) – – – – – –
68 3 0 3 0 2 (10) – – – – – –
69 2 0 1 1 2 (9) – – – Obt_R Y 0.958
71 1 1 0 0 1 (9) – – – – – –
72 3 1 2 0 2 (9) – – – – – –
75 3 0 2 1 3 (9) – – – – – –
All 106 12 47 47 85 (335) 7 TP patients 7 TP
regions





AoBif ¼ aortic bifurcation region, Ext_R/L ¼ external iliac region right/left, Int_R/L ¼ internal iliac region right/left, ITC ¼ isolated tumor cells,
macro ¼ macrometastasis, micro ¼ micrometastasis, N ¼ no, Obt_R/L ¼ obturator fossa Right/Left, TP ¼ true positive, Y ¼ yes.
aAffected lymph node(s).
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visible on 11C-choline PET-CT, we found a low (patient-
based) sensitivity of 18.9% for nodal staging. In literature,
contradictory results on nodal staging using choline PET-
CT have been reported with some studies concluding that
the use of choline PET(-CT) should be abandoned for this
purpose, whereas other authors demonstrated encouraging
results (Table 5) [12–20]. Evangelista et al. summarized the
available literature on the use of choline PET(-CT) for
nodal staging in PCa until January 2012 and attributed the
conﬂicting evidence to the relatively small sample sizes, the
inhomogeneous spectrum of patients, and the low numberof examined LNs in some studies. When revising 10 studies
with 441 patients, they obtained a (patient-based) pooled
sensitivity of 49.2% and pooled speciﬁcity of 95% [15].
Similar to other authors, they held the limited spatial
resolution of the present PET-CT systems responsible for
the high false-negative rate, as this hampers the detection of
small tumor volumes. To test this hypothesis in our patient
population, we repeated the region-based analysis only
taking into account macrometastases (Z2 mm), which did
not result into an improved performance. Although choline
PET-CT might not be ideal for nodal staging in PCa, it
could be useful for the detection of recurrent disease after
Table 4
Number of true positives, true negatives, false positives, and false negatives
and sensitivity, speciﬁcity, and accuracy for nodal staging when 11C-
choline PET-CT and diffusion-weighted MRI are combined (74 patients)
Combined 11C-choline
PET-CT and DW MRI
Patient-based analysis Region-based analysis
True positive 16 Patients 14 LN regions
True negative 32 Patients 568 LN regions
False positive 6 Patients 19 LN regions
False negative 20 Patients 70 LN regions
Sensitivity 44.4% (28.0%–60.9%) 16.7% (7.1%–26.2%)
Speciﬁcity 84.2% (72.5%–96.0%) 96.8% (95.1%–98.4%)
PPV 72.7% (53.7%–91.8%) 42.4% (24.6%–60.3%)
NPV 61.5% (48.2%–74.9%) 89.0% (85.3%–92.7%)
Accuracy 64.9% (53.9%–75.8%) 86.7% (83.0%–90.4%)
NPV ¼ negative predictive value.
Numbers between parentheses are 95% conﬁdence intervals.
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such as bladder cancer [24,25].
Although results with DW MRI are promising in some
other cancer types, data on the pretreatment diagnosis of
PCa LN metastases using DW MRI are very limited [26–
29]. Positive results were obtained in a study with 29
patients (118 LNs), reporting a sensitivity and speciﬁcity of
86.0% and 85.3%, respectively (LN-based analysis) [30]. It
should be noted that histopathology served as a reference in
only 10 of 29 patients (45 LN), whereas clinical follow-up
data were used for the remaining 19 patients (73 LNs).
Moreover, their inclusion criteria differed from ours, as they
only selected patients at a high clinical suspicion for LN
metastases, which likely resulted in an overestimation of the
diagnostic performance. These differences could in part
explain the discordance with our results. A second study
performed by Heck et al. analyzed DW MRI from 33
patients who underwent RP and extended lymph node
dissection, reporting sensitivities of approximately 57%
for the patient-based analysis and 56% for the ﬁeld-based
analysis. Although these numbers are signiﬁcantly higher
than in our study, they obtained comparable accuracies
and came to the same conclusion that the data are not
convincing to introduce DW MRI into our daily routine for
preoperative LN staging [17]. Similar to 11C-choline PET-
CT, we repeated the region-based analysis for macrometa-
stases only (Z2 mm), which led to an increase in sensitivityTable 5
Literature overview for lymph node staging in prostate cancer using choline PET
Patient-based analysis Patients, n Sensitivity, % P
Beheshti et al. [12] 130 45
Contractor et al. [13] 26 78
de Jong et al. [14] 67 80
Häcker et al. [16] 20 10
Heck et al. [17] 33 57
Husarik et al. [18] 43 20 1
Poulsen et al. [19] 210 73
Schiavina et al. [20] 57 60but a clinically acceptable level could not be reached. We
thus demonstrate that a certain tumor burden is required to
detect nodal PCa metastases by means of imaging, but these
data also suggest that this cannot be the sole explanation for
the discouraging results.
Finally, we investigated the combination of both imaging
modalities, which resulted into only a moderate increase in
sensitivity. The only other study assessing the use of DW
MRI for nodal staging in combination with 11C-choline
PET-CT was published by Beer et al. [31] and was set up to
compare ADC values and standardized uptake values
obtained from 14 patients. They concluded that ADC could
serve as a new potential biomarker providing additional
information on tumor pathophysiology compared with
standardized uptake value. Proper comparison with our
data is hampered by the exclusive analysis of LN larger
than 5 mm and by the lack of a histopathological reference
in 9 of 14 included patients.
This study can be considered a landmark trial for several
reasons. Firstly, its prospective setup and the inclusion
criteria that we employed, only allowing for patients who
were node negative on contrast-enhanced CT scan, guaran-
tee the clinical validity of this trial. Furthermore, the
number of patients enrolled was relatively high with a
uniquely high event rate of approximately 50% Nþ patients
and 106 positive nodes. The most important strength of this
study is the homogeneously deﬁned seLND template that
was used completed with a sentinel node procedure,
assuring a histopathological gold standard for the predom-
inant draining LN regions. Moreover, meticulous histopa-
thological examination was performed based on pankeratin-
stained, serial sections of all of the 1,665 LNs to assure that
no affected LN was missed and dimensions of every
malignant LN were recorded.
A potential limitation of this study could be that LN
region boundaries are, to some extent, open to interpreta-
tion, e.g., a presumed positive LN in the obturator fossa
could have been assigned to the internal iliac region during
surgery. However, this would not have affected the per-
patient results, which were disappointing as well. Regarding
the subanalysis we performed, one could criticize that the
2-mm cutoff for macrometastases we handled was too small
when considering the spatial resolution of the imaging
modalities. However, only 11 macrometastases in this study-CT
PV, % Limitation
82 Lack of histologic veriﬁcation of LN in 15% of patients
70 Small sample size
86 Lack of histologic veriﬁcation of LN in 36% of patients
33 Small sample size
80 Small sample size
00 Only obturator LN removed
59 Low number of removed LNs
90 Low number of removed LNs
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have missed no less than 9 Nþ and DW MRI 8 Nþ.5. Conclusions
Based on the low sensitivity values obtained for both
11C-choline PET-CT and DW MRI, we conclude that there
is no indication for routine clinical use of these functional
imaging techniques in the pretreatment workup for LN
staging in patients with PCa with negative ﬁndings on a CT
scan.Appendix A. Supporting Information
Supplementary material cited in this article is available
online at http://dx.doi.org/10.1016/j.urolonc.2014.11.008.References
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